MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
Cell Death Dis
; 8(10): e3126, 2017 10 12.
Article
in En
| MEDLINE
| ID: mdl-29022893
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Erythroblastic, Acute
/
Cyclin-Dependent Kinase Inhibitor p21
/
Enhancer of Zeste Homolog 2 Protein
/
N-Myc Proto-Oncogene Protein
Limits:
Humans
Language:
En
Journal:
Cell Death Dis
Year:
2017
Document type:
Article
Affiliation country:
China
Country of publication:
United kingdom